NCT05564377 · National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
What this study is about
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.
View original scientific description
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials.
Interventions
DRUG
Alpelisib
Given PO
DRUG
Binimetinib
Given PO
PROCEDURE
Biopsy Procedure
Undergo biopsy
PROCEDURE
Biospecimen Collection
Undergo blood collection
PROCEDURE
Bone Marrow Aspiration
Undergo bone marrow aspiration
PROCEDURE
Bone Marrow Biopsy
Undergo bone marrow biopsy
PROCEDURE
Bone Scan
Undergo bone scan
PROCEDURE
Computed Tomography
Undergo CT
PROCEDURE
Echocardiography Test
Undergo ECHO
DRUG
Fluorouracil
Given IV
DRUG
Fulvestrant
Given IM
DRUG
Ipatasertib
Given PO
DRUG
Leucovorin
Given IV
PROCEDURE
Magnetic Resonance Imaging
Undergo MRI
PROCEDURE
Multigated Acquisition Scan
Undergo MUGA
PROCEDURE
Mutation Carrier Screening
Undergo tumor mutational screening
DRUG
Neratinib Maleate
Given PO
DRUG
Nilotinib Hydrochloride Monohydrate
Given PO
DRUG
Olaparib
Given PO
DRUG
Oxaliplatin
Given IV
DRUG
Paclitaxel
Given PO or IV
DRUG
Palbociclib
Given PO
BIOLOGICAL
Panitumumab
Given IV
PROCEDURE
Positron Emission Tomography
Undergo PET
DRUG
Selumetinib Sulfate
Given PO
DRUG
Sotorasib
Given PO
Primary outcome measures
Accrual of patients to ComboMATCH treatment trials
Time frame: Up to 8 years
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations).
Assignment of patients to ComboMATCH treatment trials
Time frame: Up to 8 years
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations).
Enrollment rates to ComboMATCH treatment trials
Time frame: Up to 8 years
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations).
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Patient must have measurable disease
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of \>= 50% or Karnofsky performance status of \>= 50%
- Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider
- All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL)
- Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria:
- Patients must have progressed on at least one line of standard systemic therapy OR
- Patients whose disease has no standard treatment that has been shown to prolong overall survival
- Patient must meet one of the following requirements:
- Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision
Where
- Birmingham, Alabama
- Mobile, Alabama
- Anchorage, Alaska
- Goodyear, Arizona
- Kingman, Arizona
- Phoenix, Arizona
- Jonesboro, Arkansas
- Arroyo Grande, California
- Carmichael, California
- Dublin, California
- Elk Grove, California
- Encinitas, California
And 344 more locations — see the full list below.
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 15, 2026 · Source of record for eligibility and locations